减少传播、健康收益与提高抗逆转录病毒治疗保留率干预措施的成本上限:三项数学模型的联合分析
该联合分析利用EMOD(南非)、Optima(马拉维)和Synthesis(撒哈拉以南非洲低收入和中等收入国家)三个HIV模型,从2022年1月1日起模拟40年,评估提高ART保留率干预措施的感染避免数、伤残调整生命年(DALY)避免数和成本上限。每增加一人年ART保留,可避免1.35-3.55个DALY和0.12-0.20例感染。成本上限因场景和干预效果而异。
要点
- 三个模型均显示,每增加一人年ART保留,可避免1.35-3.55个DALY和0.12-0.20例感染。
- 在全体ART患者中提高25%保留率,成本上限为:Optima(马拉维)每人年2-6美元,Synthesis(撒哈拉以南非洲LMICs)43-68美元,EMOD(南非)28-180美元。
- 最大程度靶向且有效的保留干预,成本上限为:Optima(马拉维)每人年93-223美元,Synthesis(LMICs)871-1389美元,EMOD(南非)1013-6518美元。
核心结论
- 提高ART保留率的成本上限在撒哈拉以南非洲不同场景间存在差异,且可能等于或高于全民治疗时代开始前的估计值。
- 通过将干预措施靶向针对中断ART风险最高的人群,可提高成本上限。
研究设计与样本
- 联合分析,比较三个结构、假设和基线设置不同的HIV模型:EMOD(南非)、Optima(马拉维)和Synthesis(撒哈拉以南非洲低收入和中等收入国家)。
- 模拟时间范围为40年,从2022年1月1日(干预实施基线)至2062年1月1日。
- 变化参数包括ART保留率增量(25%、50%、75%和100%保留)、干预靶向中断ART风险个体的程度以及各场景的成本效果阈值。
主要发现
- 三个模型对每增加一人年ART保留的健康收益(即避免的DALY)和传播减少给出了consistent估计:在40年时间范围内避免1.35-3.55个DALY和0.12-0.20例感染。
- 在全体接受ART者中(无论中断ART风险如何)提高25%保留率,每人年成本上限为:Optima(马拉维)2-6美元,Synthesis(撒哈拉以南非洲LMICs)43-68美元,EMOD(南非)28-180美元。
- 最大程度靶向且有效的保留干预,每人年成本上限为:Optima(马拉维)93-223美元,Synthesis(撒哈拉以南非洲LMICs)871-1389美元,EMOD(南非)1013-6518美元。
- 成本上限因场景和干预效果而异。
关键数值与推荐
- 每增加一人年ART保留,避免1.35-3.55个DALY和0.12-0.20例感染(40年时间范围)。
- 全体ART患者中提高25%保留率的成本上限:Optima(马拉维)每人年2-6美元,Synthesis(撒哈拉以南非洲LMICs)43-68美元,EMOD(南非)28-180美元。
- 最大程度靶向且有效的保留干预的成本上限:Optima(马拉维)每人年93-223美元,Synthesis(撒哈拉以南非洲LMICs)871-1389美元,EMOD(南非)1013-6518美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this so-called treat-all era, antiretroviral therapy (ART) interruptions contribute to an increasing proportion of HIV infections and deaths. Many strategies to improve retention on ART cost more than standard of care. In this study, we aimed to estimate the upper-bound costs at which such interventions should be adopted. METHODS: In this combined analysis, we compared the infections averted, disability-adjusted life-years (DALYs) averted, and upper-bound costs of interventions that improve ART retention in three HIV models with diverse structures, assumptions, and baseline settings: EMOD in South Africa, Optima in Malawi, and Synthesis in sub-Saharan African low-income and middle-income countries (LMICs). We modelled estimates over a 40-year time horizon, from a baseline of Jan 1, 2022, when interventions would be implemented, to Jan 1, 2062. We varied increment of ART retention (25%, 50%, 75%, and 100% retention), the extent to which interventions could be targeted towards individuals at risk of interrupting ART, and cost-effectiveness thresholds in each setting. FINDINGS: Despite simulating different settings and epidemic trends, all three models produced consistent estimates of health benefit (ie, DALYs averted) and transmission reduction per increment in retention. The range of estimates was 1·35-3·55 DALYs and 0·12-0·20 infections averted over the 40-year time horizon per additional person-year retained on ART. Upper-bound costs varied by setting and intervention effectiveness. Improving retention by 25% among all people receiving ART, regardless of risk of ART interruption, gave an upper-bound cost per person-year of US$2-6 in Optima (Malawi), $43-68 in Synthesis (LMICs in sub-Saharan Africa), and $28-180 in EMOD (South Africa). A maximally targeted and effective retention intervention had an upper-bound cost per person-year of US$93-223 in Optima (Malawi), $871-1389 in Synthesis (LMICs in sub-Saharan Africa), and $1013-6518 in EMOD (South Africa). INTERPRETATION: Upper-bound costs that could improve ART retention vary across sub-Saharan African settings and are likely to be similar to or higher than was estimated before the start of the treat-all era. Upper-bound costs could be increased by targeting interventions to those most at risk of interrupting ART. FUNDING: Bill & Melinda Gates Foundation.
引用
- Bershteyn A, Jamieson L, Kim HY, et al. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022. PMID: 35961353. doi:10.1016/S2214-109X(22)00310-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。